HIV+ progressive multifocal leukoencephalopathy (PML) patients had a significantly lower expression of CD62L on CD4+ T cells (P < 0.001) when compared with HIV+ patients who did not develop PML. CD62L expression on CD4+ T cells did not correlate with parameters such as CDC stage, CD4+ cell percentage (of total CD3+ T cells), CD4+ cell counts, virus count, or clinical parameters. Measurement of CD62L might provide a biomarker for PML risk and could prompt a treatment change and/or close monitoring.
Department of Neurology, University of Münster, Münster, Germany.
Correspondence to Dr Tilman Schneider-Hohendorf, Department of Neurology, University of Münster, Albert-Schweitzer-Campus-1, Building A01, 48149 Münster, Germany. Tel: +49 251 980 2885; e-mail: email@example.com
Received 10 December, 2013
Revised 6 January, 2014
Accepted 6 January, 2014
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).